Drug Trial Radar · NCT06388772
Study to Assess PK, Safety and Tolerability Early in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Jul 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
74
Actual
Start
Jul 5, 2021
Primary completion
Jul 22, 2022
Study completion Jan 6, 2023
Sponsor
- Lead sponsor
- Changzhou Qianhong Bio-pharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of QHRD106 early in Chinese healthy subjects with single doses.
Conditions
- Acute Ischemic Stroke
Interventions
QHRD106 InjectionDrug
250IU\~8400IU,pegylated(PEG)-tissue kallikrein-1
placeboDrug
placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety as assessed by incidence, severity, and causality of adverse eventsTime frame: Up to 36 days after final dose
- Plasma measurements of QHRD106Time frame: Up to 36 days after final dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.